Literature DB >> 14499246

CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro.

Janelle R Salkowitz1, Shannon E Bruse, Howard Meyerson, Hernan Valdez, Donald E Mosier, Clifford V Harding, Peter A Zimmerman, Michael M Lederman.   

Abstract

The common CCR5 promoter polymorphism at position -2459 (A/G) has been associated with differences in the rate of progression to AIDS, where HIV-1-infected individuals with the CCR5 -2459 G/G genotype exhibit slower disease progression than those with the A/A genotype. Mechanisms underlying the relationship between these polymorphisms and disease progression are not known. Here through in vitro infection of peripheral blood mononuclear cells obtained from healthy Caucasian blood donors with macrophage-tropic HIV-1 isolates we observed low, medium, and high viral propagation in association with G/G, A/G, and A/A promoter genotypes, respectively. Flow cytometric analysis of unstimulated CD14+ monocytes from these same donors revealed a similar hierarchy of CCR5 receptor density in association with promoter genotypes. Finally, PBMC from persons with the G/G promoter polymorphism produced higher levels of beta-chemokines after in vitro stimulation. Thus, the CCR5 -2459 (A/G) promoter polymorphism determines CCR5 expression and predicts the magnitude of HIV-1 propagation in vitro. These findings may provide important insight regarding the regulation of mechanisms that influence the rate of HIV-1 propagation and progression to AIDS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14499246      PMCID: PMC3728895          DOI: 10.1016/s1521-6616(03)00147-5

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  32 in total

1.  Association of the CCR5delta32 mutation with improved response to antiretroviral therapy.

Authors:  H Valdez; S F Purvis; M M Lederman; M Fillingame; P A Zimmerman
Journal:  JAMA       Date:  1999-08-25       Impact factor: 56.272

2.  Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines.

Authors:  W A Paxton; R Liu; S Kang; L Wu; T R Gingeras; N R Landau; C R Mackay; R A Koup
Journal:  Virology       Date:  1998-04-25       Impact factor: 3.616

3.  Quantitation of CD38 expression using QuantiBRITE beads.

Authors:  S B Iyer; L E Hultin; J A Zawadzki; K A Davis; J V Giorgi
Journal:  Cytometry       Date:  1998-10-01

4.  C-C chemokines, pivotal in protection against HIV type 1 infection.

Authors:  D Zagury; A Lachgar; V Chams; L S Fall; J Bernard; J F Zagury; B Bizzini; A Gringeri; E Santagostino; J Rappaport; M Feldman; S J O'Brien; A Burny; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

5.  CCR5-delta 32 gene deletion in HIV-1 infected patients.

Authors:  B Wang; P Palasanthiran; J Zeigler; A Cunningham; N K Saksena
Journal:  Lancet       Date:  1997-09-06       Impact factor: 79.321

6.  HIV-1 infection in a man homozygous for CCR5 delta 32.

Authors:  T R O'Brien; C Winkler; M Dean; J A Nelson; M Carrington; N L Michael; G C White
Journal:  Lancet       Date:  1997-04-26       Impact factor: 79.321

7.  A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation.

Authors:  L G Kostrikis; Y Huang; J P Moore; S M Wolinsky; L Zhang; Y Guo; L Deutsch; J Phair; A U Neumann; D D Ho
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

8.  The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression.

Authors:  N L Michael; L G Louie; A L Rohrbaugh; K A Schultz; D E Dayhoff; C E Wang; H W Sheppard
Journal:  Nat Med       Date:  1997-10       Impact factor: 53.440

9.  Genetic acceleration of AIDS progression by a promoter variant of CCR5.

Authors:  M P Martin; M Dean; M W Smith; C Winkler; B Gerrard; N L Michael; B Lee; R W Doms; J Margolick; S Buchbinder; J J Goedert; T R O'Brien; M W Hilgartner; D Vlahov; S J O'Brien; M Carrington
Journal:  Science       Date:  1998-12-04       Impact factor: 47.728

10.  CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS).

Authors:  D H McDermott; P A Zimmerman; F Guignard; C A Kleeberger; S F Leitman; P M Murphy
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

View more
  46 in total

1.  A haplotype in the CCR5 gene promoter was associated with the susceptibility to HIV-1 infection in a northern Chinese population.

Authors:  Lidan Xu; Yuandong Qiao; Xuelong Zhang; Haiming Sun; Jingwei Wang; Donglin Sun; Xueyuan Jia; Chao Shen; Yanling Zhao; Yan Jin; Yang Yu; Hong Ling; Kaili Wang; Songbin Fu
Journal:  Mol Biol Rep       Date:  2010-04-04       Impact factor: 2.316

2.  TCR triggering transcriptionally downregulates CCR5 expression on rhesus macaque CD4(+) T-cells with no measurable effect on susceptibility to SIV infection.

Authors:  Jacob T Minang; Matthew T Trivett; Eugene V Barsov; Gregory Q Del Prete; Charles M Trubey; James A Thomas; Robert J Gorelick; Michael Piatak; David E Ott; Claes Ohlen
Journal:  Virology       Date:  2010-10-28       Impact factor: 3.616

Review 3.  Resistance to HIV infection.

Authors:  M Marmor; K Hertzmark; S M Thomas; P N Halkitis; M Vogler
Journal:  J Urban Health       Date:  2006-01       Impact factor: 3.671

4.  Concordance of CCR5 genotypes that influence cell-mediated immunity and HIV-1 disease progression rates.

Authors:  Gabriel Catano; Zoya A Chykarenko; Andrea Mangano; J-M Anaya; Weijing He; Alison Smith; Rosa Bologna; Luisa Sen; Robert A Clark; Andrew Lloyd; Ludmila Shostakovich-Koretskaya; Sunil K Ahuja
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

Review 5.  Mendelian randomization: potential use of genetics to enable causal inferences regarding HIV-associated biomarkers and outcomes.

Authors:  Weijing He; John Castiblanco; Elizabeth A Walter; Jason F Okulicz; Sunil K Ahuja
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

6.  Cis-regulatory genetic variants in the CCR5 gene and natural HIV-1 control in black South Africans.

Authors:  Gemma W Koor; Maria Paximadis; Anabela C P Picton; Fidan Karatas; Shayne A Loubser; Weijing He; Sunil K Ahuja; Richard E Chaisson; Neil Martinson; Osman Ebrahim; Caroline T Tiemessen
Journal:  Clin Immunol       Date:  2019-05-15       Impact factor: 3.969

7.  Double-edged genetic swords and immunity: lesson from CCR5 and beyond.

Authors:  Sunil K Ahuja; Weijing He
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

8.  Influence of CCR5 and CCR2 genetic variants in the resistance/susceptibility to HIV in serodiscordant couples from Colombia.

Authors:  Wildeman Zapata; Wbeimar Aguilar-Jiménez; Nicolás Pineda-Trujillo; Winston Rojas; Hernando Estrada; María T Rugeles
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-09       Impact factor: 2.205

9.  Genetic variation within the gene encoding the HIV-1 CCR5 coreceptor in two South African populations.

Authors:  Anabela C P Picton; Maria Paximadis; Caroline T Tiemessen
Journal:  Infect Genet Evol       Date:  2010-03-04       Impact factor: 3.342

10.  Regulation of CCR5 expression in human placenta: insights from a study of mother-to-child transmission of HIV in Malawi.

Authors:  Bonnie R Joubert; Nora Franceschini; Victor Mwapasa; Kari E North; Steven R Meshnick
Journal:  PLoS One       Date:  2010-02-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.